Nonopioid analgesics discovery and the Valley of Death: EMA401 from concept to clinical trial

MT Smith - Pain, 2022 - journals.lww.com
Globally, the prevalence of chronic pain is high at 10% to 50% of the adult population. 18,
23, 40, 57, 63, 64 Chronic pain not only impairs the quality of life of patients and their …

Aligning New Approaches to Accelerate the Development of Non-opioid Analgesic Therapies

CN Sang, WK Schmidt - Neurotherapeutics, 2020 - Springer
The opioid epidemic has transformed pain research, not only in the sense of urgency with
which analgesics are being developed, but also in the way in which hypotheses are being …

Contemporary and emergent pharmacological therapies for chronic pain: nonopioid analgesia

JM Cox, M Pappagallo - Expert Review of Neurotherapeutics, 2001 - Taylor & Francis
The American Pain Society estimates that 50 million Americans are partially or totally
disabled by pain. This striking statistic is certain to increase as our population continues to …

[PDF][PDF] Re-energizing the development of pain therapeutics in light of the opioid epidemic

P Skolnick, ND Volkow - Neuron, 2016 - cell.com
Limited options for treating moderate-severe pain led to an overreliance on opioids and the
current opioid epidemic. Addressing the factors contributing to a dearth of effective …

[HTML][HTML] Pain—novel targets and new technologies

S Hua, PJ Cabot - Frontiers in Pharmacology, 2014 - frontiersin.org
Pain is a major health problem that significantly affects the quality of life of patients. It has a
significant impact on both the sufferers and the broader community, imparting high health …

Development of new analgesics: an answer to opioid epidemic

TL Yaksh, MA Hunt, GG Dos Santos - Trends in Pharmacological Sciences, 2018 - cell.com
Management of pain is a fundamental imperative in medicine. Current analgesics suffer from
limitations related to efficacy and adverse events of which abuse potential has assumed an …

Breaking barriers to novel analgesic drug development

AS Yekkirala, DP Roberson, BP Bean… - Nature reviews Drug …, 2017 - nature.com
Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …

[PDF][PDF] Receptor and molecular targets for the development of novel opioid and non-opioid analgesic therapies

R Chen, M Coppes, RD Urman - Pain Physician, 2021 - painphysicianjournal.com
Background: Although conventional pain relief therapeutics have centered around μ-opioid
agonists, these drugs are limited by adverse side effects, including respiratory depression …

[HTML][HTML] Non-pharmacological treatment of pain: Grand challenge and future opportunities

MC Bushnell, E Frangos, N Madian - Frontiers in Pain Research, 2021 - frontiersin.org
The “Non-pharmacological treatment of pain” section of the Frontiers in Pain Research was
initiated to reflect the growing appreciation for the role that complementary interventions play …

Opportunities and challenges for nonaddictive interventions in chronic pain

V Malafoglia, M Tenti, S Ilari, E Balzani, A Fanelli… - Current opinion in …, 2021 - Elsevier
The worlds of chronic pain and addiction continue to intersect too often in many ways.
Chronic pain significantly impairs and disrupts the quality of life of millions of people …